Clinical information of patients with UC who received RPC with IPAA, comparing between patients with and without pouchitis.
| Patients with UC who received RPC with IPAA . | ||||
|---|---|---|---|---|
| Total . | With pouchitis . | Without pouchitis . | P-value . | |
| Number of patients, n | 16 | 6 | 10 | |
| Median age at RPC, years (range) | 49.5 (25-76) | 41.5 (25-48) | 55.0 (47-76) | .0005 |
| Median disease duration before RPC, years (range) | 9.45 (0.3-32.4) | 8.9 (0.3-22.3) | 11.3 (1.1-32.4) | .3676 |
| Median observation period, years (range) | 3.47 (1.4-4.8) | 3.8 (2.3-4.8) | 2.4 (1.4-4.8) | .1882 |
| Median period from RPC to ileostomy closure, days (range) | 107 (0-407) | 94 (0-147) | 115 (0-407) | .4850 |
| Sex | ||||
| Male, n (%) | 8 (50.0%) | 3 (50.0%) | 5 (50.0%) | 1.0000 |
| Female, n (%) | 8 (50.0%) | 3 (50.0%) | 5 (50.0%) | |
| Smoking | ||||
| Past smoker, n (%) | 7 (43.8%) | 1 (16.7%) | 6 (60.0%) | .1451 |
| Never smoker, n (%) | 9 (56.3%) | 5 (83.3%) | 4 (40.0%) | |
| Extraintestinal manifestation, n | 0 | 0 | 0 | |
| Cause of RPC, n (%) | ||||
| Refractory | 4 (25.0%) | 1 (16.7%) | 3 (30.0%) | .1037 |
| CAC | 11 (68.8%) | 5 (83.3%) | 6 (60.0%) | |
| Stenosis | 1 (6.3%) | 0 | 1 (10.0%) | |
| Extent of UC, n (%) | ||||
| Pancolitis | 12 (75.0%) | 6 (100%) | 6 (60.0%) | .2335 |
| Left-sided colitis | 4 (25.0%) | 0 | 4 (40.0%) | |
| Median pMS (range) | 1.5 (1-9) | 1 (1-9) | 2.5 (1-8) | .5210 |
| Median MES (range) | 2 (1-3) | 2 (1-2) | 2 (1-3) | 1.0000 |
| Treatment of UC at RPC, n (%) | ||||
| 5-Aminosalicylic acid | 16 (100%) | 6 (100%) | 10 (100%) | 1.0000 |
| Corticosteroid | 0 | 0 | 0 | |
| Immunomodulator | 8 (50.0%) | 3 (50.0%) | 5 (50.0%) | 1.0000 |
| Biological agent | 6 (37.5%) | 2 (33.3%) | 4 (40.0%) | 1.0000 |
| Calcineurin inhibitor | 2 (12.5%) | 1 (16.7%) | 1 (10.0%) | 1.0000 |
| Apheresis | 0 | 0 | 0 | |
| Previous treatment of UC, n (%) | ||||
| 5-Aminosalicylic acid | 16 (100%) | 6 (100%) | 10 (100%) | 1.0000 |
| Corticosteroid | 9 (56.3%) | 3 (50.0%) | 6 (60.0%) | 1.0000 |
| Immunomodulator | 11 (68.8%) | 4 (66.7%) | 7 (70.0%) | 1.0000 |
| Biological agent | 9 (56.3%) | 4 (66.7%) | 5 (50.0%) | .6329 |
| Calcineurin inhibitor | 4 (25.0%) | 1 (16.7%) | 3 (30.0%) | 1.0000 |
| Apheresis | 8 (50.0%) | 2 (33.3%) | 6 (60.0%) | 1.0000 |
| Surgical procedure, n (%) | ||||
| IPAA | 10 (62.5%) | 2 (33.3%) | 8 (80.0%) | .1181 |
| IPACA | 6 (37.5%) | 4 (66.7%) | 2 (20.0%) | |
| Patients with UC who received RPC with IPAA . | ||||
|---|---|---|---|---|
| Total . | With pouchitis . | Without pouchitis . | P-value . | |
| Number of patients, n | 16 | 6 | 10 | |
| Median age at RPC, years (range) | 49.5 (25-76) | 41.5 (25-48) | 55.0 (47-76) | .0005 |
| Median disease duration before RPC, years (range) | 9.45 (0.3-32.4) | 8.9 (0.3-22.3) | 11.3 (1.1-32.4) | .3676 |
| Median observation period, years (range) | 3.47 (1.4-4.8) | 3.8 (2.3-4.8) | 2.4 (1.4-4.8) | .1882 |
| Median period from RPC to ileostomy closure, days (range) | 107 (0-407) | 94 (0-147) | 115 (0-407) | .4850 |
| Sex | ||||
| Male, n (%) | 8 (50.0%) | 3 (50.0%) | 5 (50.0%) | 1.0000 |
| Female, n (%) | 8 (50.0%) | 3 (50.0%) | 5 (50.0%) | |
| Smoking | ||||
| Past smoker, n (%) | 7 (43.8%) | 1 (16.7%) | 6 (60.0%) | .1451 |
| Never smoker, n (%) | 9 (56.3%) | 5 (83.3%) | 4 (40.0%) | |
| Extraintestinal manifestation, n | 0 | 0 | 0 | |
| Cause of RPC, n (%) | ||||
| Refractory | 4 (25.0%) | 1 (16.7%) | 3 (30.0%) | .1037 |
| CAC | 11 (68.8%) | 5 (83.3%) | 6 (60.0%) | |
| Stenosis | 1 (6.3%) | 0 | 1 (10.0%) | |
| Extent of UC, n (%) | ||||
| Pancolitis | 12 (75.0%) | 6 (100%) | 6 (60.0%) | .2335 |
| Left-sided colitis | 4 (25.0%) | 0 | 4 (40.0%) | |
| Median pMS (range) | 1.5 (1-9) | 1 (1-9) | 2.5 (1-8) | .5210 |
| Median MES (range) | 2 (1-3) | 2 (1-2) | 2 (1-3) | 1.0000 |
| Treatment of UC at RPC, n (%) | ||||
| 5-Aminosalicylic acid | 16 (100%) | 6 (100%) | 10 (100%) | 1.0000 |
| Corticosteroid | 0 | 0 | 0 | |
| Immunomodulator | 8 (50.0%) | 3 (50.0%) | 5 (50.0%) | 1.0000 |
| Biological agent | 6 (37.5%) | 2 (33.3%) | 4 (40.0%) | 1.0000 |
| Calcineurin inhibitor | 2 (12.5%) | 1 (16.7%) | 1 (10.0%) | 1.0000 |
| Apheresis | 0 | 0 | 0 | |
| Previous treatment of UC, n (%) | ||||
| 5-Aminosalicylic acid | 16 (100%) | 6 (100%) | 10 (100%) | 1.0000 |
| Corticosteroid | 9 (56.3%) | 3 (50.0%) | 6 (60.0%) | 1.0000 |
| Immunomodulator | 11 (68.8%) | 4 (66.7%) | 7 (70.0%) | 1.0000 |
| Biological agent | 9 (56.3%) | 4 (66.7%) | 5 (50.0%) | .6329 |
| Calcineurin inhibitor | 4 (25.0%) | 1 (16.7%) | 3 (30.0%) | 1.0000 |
| Apheresis | 8 (50.0%) | 2 (33.3%) | 6 (60.0%) | 1.0000 |
| Surgical procedure, n (%) | ||||
| IPAA | 10 (62.5%) | 2 (33.3%) | 8 (80.0%) | .1181 |
| IPACA | 6 (37.5%) | 4 (66.7%) | 2 (20.0%) | |
Abbreviations: CAC, colitis-associated cancer; IPAA, ileal pouch-anal anastomosis; IPACA, ileal pouch-anal canal anastomosis; MES, Mayo Endoscopic Subscore; pMS, partial Mayo Score; RPC, restorative proctocolectomy; UC, ulcerative colitis. Statistical analysis was performed using Mann-Whitney U test for continuous variables, and Fisher’s exact test for categorical variables.
Clinical information of patients with UC who received RPC with IPAA, comparing between patients with and without pouchitis.
| Patients with UC who received RPC with IPAA . | ||||
|---|---|---|---|---|
| Total . | With pouchitis . | Without pouchitis . | P-value . | |
| Number of patients, n | 16 | 6 | 10 | |
| Median age at RPC, years (range) | 49.5 (25-76) | 41.5 (25-48) | 55.0 (47-76) | .0005 |
| Median disease duration before RPC, years (range) | 9.45 (0.3-32.4) | 8.9 (0.3-22.3) | 11.3 (1.1-32.4) | .3676 |
| Median observation period, years (range) | 3.47 (1.4-4.8) | 3.8 (2.3-4.8) | 2.4 (1.4-4.8) | .1882 |
| Median period from RPC to ileostomy closure, days (range) | 107 (0-407) | 94 (0-147) | 115 (0-407) | .4850 |
| Sex | ||||
| Male, n (%) | 8 (50.0%) | 3 (50.0%) | 5 (50.0%) | 1.0000 |
| Female, n (%) | 8 (50.0%) | 3 (50.0%) | 5 (50.0%) | |
| Smoking | ||||
| Past smoker, n (%) | 7 (43.8%) | 1 (16.7%) | 6 (60.0%) | .1451 |
| Never smoker, n (%) | 9 (56.3%) | 5 (83.3%) | 4 (40.0%) | |
| Extraintestinal manifestation, n | 0 | 0 | 0 | |
| Cause of RPC, n (%) | ||||
| Refractory | 4 (25.0%) | 1 (16.7%) | 3 (30.0%) | .1037 |
| CAC | 11 (68.8%) | 5 (83.3%) | 6 (60.0%) | |
| Stenosis | 1 (6.3%) | 0 | 1 (10.0%) | |
| Extent of UC, n (%) | ||||
| Pancolitis | 12 (75.0%) | 6 (100%) | 6 (60.0%) | .2335 |
| Left-sided colitis | 4 (25.0%) | 0 | 4 (40.0%) | |
| Median pMS (range) | 1.5 (1-9) | 1 (1-9) | 2.5 (1-8) | .5210 |
| Median MES (range) | 2 (1-3) | 2 (1-2) | 2 (1-3) | 1.0000 |
| Treatment of UC at RPC, n (%) | ||||
| 5-Aminosalicylic acid | 16 (100%) | 6 (100%) | 10 (100%) | 1.0000 |
| Corticosteroid | 0 | 0 | 0 | |
| Immunomodulator | 8 (50.0%) | 3 (50.0%) | 5 (50.0%) | 1.0000 |
| Biological agent | 6 (37.5%) | 2 (33.3%) | 4 (40.0%) | 1.0000 |
| Calcineurin inhibitor | 2 (12.5%) | 1 (16.7%) | 1 (10.0%) | 1.0000 |
| Apheresis | 0 | 0 | 0 | |
| Previous treatment of UC, n (%) | ||||
| 5-Aminosalicylic acid | 16 (100%) | 6 (100%) | 10 (100%) | 1.0000 |
| Corticosteroid | 9 (56.3%) | 3 (50.0%) | 6 (60.0%) | 1.0000 |
| Immunomodulator | 11 (68.8%) | 4 (66.7%) | 7 (70.0%) | 1.0000 |
| Biological agent | 9 (56.3%) | 4 (66.7%) | 5 (50.0%) | .6329 |
| Calcineurin inhibitor | 4 (25.0%) | 1 (16.7%) | 3 (30.0%) | 1.0000 |
| Apheresis | 8 (50.0%) | 2 (33.3%) | 6 (60.0%) | 1.0000 |
| Surgical procedure, n (%) | ||||
| IPAA | 10 (62.5%) | 2 (33.3%) | 8 (80.0%) | .1181 |
| IPACA | 6 (37.5%) | 4 (66.7%) | 2 (20.0%) | |
| Patients with UC who received RPC with IPAA . | ||||
|---|---|---|---|---|
| Total . | With pouchitis . | Without pouchitis . | P-value . | |
| Number of patients, n | 16 | 6 | 10 | |
| Median age at RPC, years (range) | 49.5 (25-76) | 41.5 (25-48) | 55.0 (47-76) | .0005 |
| Median disease duration before RPC, years (range) | 9.45 (0.3-32.4) | 8.9 (0.3-22.3) | 11.3 (1.1-32.4) | .3676 |
| Median observation period, years (range) | 3.47 (1.4-4.8) | 3.8 (2.3-4.8) | 2.4 (1.4-4.8) | .1882 |
| Median period from RPC to ileostomy closure, days (range) | 107 (0-407) | 94 (0-147) | 115 (0-407) | .4850 |
| Sex | ||||
| Male, n (%) | 8 (50.0%) | 3 (50.0%) | 5 (50.0%) | 1.0000 |
| Female, n (%) | 8 (50.0%) | 3 (50.0%) | 5 (50.0%) | |
| Smoking | ||||
| Past smoker, n (%) | 7 (43.8%) | 1 (16.7%) | 6 (60.0%) | .1451 |
| Never smoker, n (%) | 9 (56.3%) | 5 (83.3%) | 4 (40.0%) | |
| Extraintestinal manifestation, n | 0 | 0 | 0 | |
| Cause of RPC, n (%) | ||||
| Refractory | 4 (25.0%) | 1 (16.7%) | 3 (30.0%) | .1037 |
| CAC | 11 (68.8%) | 5 (83.3%) | 6 (60.0%) | |
| Stenosis | 1 (6.3%) | 0 | 1 (10.0%) | |
| Extent of UC, n (%) | ||||
| Pancolitis | 12 (75.0%) | 6 (100%) | 6 (60.0%) | .2335 |
| Left-sided colitis | 4 (25.0%) | 0 | 4 (40.0%) | |
| Median pMS (range) | 1.5 (1-9) | 1 (1-9) | 2.5 (1-8) | .5210 |
| Median MES (range) | 2 (1-3) | 2 (1-2) | 2 (1-3) | 1.0000 |
| Treatment of UC at RPC, n (%) | ||||
| 5-Aminosalicylic acid | 16 (100%) | 6 (100%) | 10 (100%) | 1.0000 |
| Corticosteroid | 0 | 0 | 0 | |
| Immunomodulator | 8 (50.0%) | 3 (50.0%) | 5 (50.0%) | 1.0000 |
| Biological agent | 6 (37.5%) | 2 (33.3%) | 4 (40.0%) | 1.0000 |
| Calcineurin inhibitor | 2 (12.5%) | 1 (16.7%) | 1 (10.0%) | 1.0000 |
| Apheresis | 0 | 0 | 0 | |
| Previous treatment of UC, n (%) | ||||
| 5-Aminosalicylic acid | 16 (100%) | 6 (100%) | 10 (100%) | 1.0000 |
| Corticosteroid | 9 (56.3%) | 3 (50.0%) | 6 (60.0%) | 1.0000 |
| Immunomodulator | 11 (68.8%) | 4 (66.7%) | 7 (70.0%) | 1.0000 |
| Biological agent | 9 (56.3%) | 4 (66.7%) | 5 (50.0%) | .6329 |
| Calcineurin inhibitor | 4 (25.0%) | 1 (16.7%) | 3 (30.0%) | 1.0000 |
| Apheresis | 8 (50.0%) | 2 (33.3%) | 6 (60.0%) | 1.0000 |
| Surgical procedure, n (%) | ||||
| IPAA | 10 (62.5%) | 2 (33.3%) | 8 (80.0%) | .1181 |
| IPACA | 6 (37.5%) | 4 (66.7%) | 2 (20.0%) | |
Abbreviations: CAC, colitis-associated cancer; IPAA, ileal pouch-anal anastomosis; IPACA, ileal pouch-anal canal anastomosis; MES, Mayo Endoscopic Subscore; pMS, partial Mayo Score; RPC, restorative proctocolectomy; UC, ulcerative colitis. Statistical analysis was performed using Mann-Whitney U test for continuous variables, and Fisher’s exact test for categorical variables.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
